RxDoctor Payments Data

Susan Newman, MD

Hematology & Oncology · Knoxville, TNNPI 1700984010

Payments from drug & device makers

$13,967in general payments, 2019–2025

Across 209 payments — averaging $66.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Merck$558
  • Novartis$458
  • Gilead$387
  • Genentech USA, Inc.$359
  • Seagen Inc.$334
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,71794%
  • Education$2506%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,967 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,557
Medicare patients
257
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib146$2,118,130
IbrancePalbociclib68$1,029,486
NerlynxNeratinib Maleate26$530,512
ImbruvicaIbrutinib26$411,954
FotivdaTivozanib Hcl12$348,074
LumakrasSotorasib17$330,212
KisqaliRibociclib Succinate16$240,718
LynparzaOlaparib15$240,617
XareltoRivaroxaban49$34,179
Letrozole634$13,482
Octreotide Acetate12$4,306
Tamoxifen Citrate104$2,416
Anastrozole107$1,747
Esomeprazole Magnesium11$1,447
Ondansetron Hcl41$1,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$25$2,118,130146 claims
PfizerIbrance$10,187$1,029,48668 claims
Puma Biotechnology, Inc.Nerlynx$48$530,51226 claims
AmgenLumakras$244$330,21217 claims
NovartisKisqali$458$240,71816 claims
AstraZenecaLynparza$259$240,61715 claims
Johnson & JohnsonXarelto$106$34,17949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →